Most Read Articles
Elaine Soliven, 20 May 2020
Early treatment with a triple antiviral combination of lopinavir-ritonavir, ribavirin, and interferon beta-1b significantly shortens the duration of virus shedding and reduces symptoms in patients with mild-to-moderate COVID-19 compared with lopinavir-ritonavir only, according to a recent study.
Pearl Toh, 26 Sep 2019
The Singapore Health Sciences Authority (HSA) has recalled eight brands of ranitidine products containing trace amounts of the nitrosamine impurity NDMA*, which is a potential human carcinogen.
Roshini Claire Anthony, 27 May 2020

The use of a vaginal cleansing intervention prior to Caesarean delivery reduced the incidence of surgical site infections (SSIs), according to a study presented at ACOG 2020. However, the addition of intravenous (IV) azithromycin prophylaxis had no added impact on SSI rates. 

Pank Jit Sin, 14 Apr 2020
With the movement control order (MCO) in full gear, most conferences and meetings are being postponed or cancelled. Some have taken to having conferences and meetings in a virtual setting, such as the recently ended American College of Cardiology/World Congress of Cardiology (ACC.20/WCC) conference. MIMS and the Asian Young Pharmacist Group (AYPG) took this opportunity to engage with pharmacists in the form of a Zoom meeting. 

CD40 blockade shows therapeutic potential in Sjögren's syndrome

02 Apr 2020

The novel anti-CD40 monoclonal antibody iscalimab has demonstrated clinical activity in patients with primary Sjögren's syndrome in a proof-of-concept study.

In the 12-week trial, 12 patients in cohort 1 were randomly assigned to receive either 3 mg/kg iscalimab (n=8) or placebo (n=4) via subcutaneous injections, whereas 32 patients in cohort 2 were randomized to receive either 10 mg/kg intravenous doses of iscalimab (n=21) or placebo (n=11). Treatment was administered at weeks 0, 2, 4 and 8.

Adverse events occurred in all patients in cohort 1, and in 52 percent of those on iscalimab and 64 percent of those on placebo in cohort 2. There were two serious adverse events documented, one was a case of bacterial conjunctivitis in cohort 1 and the other was a case of atrial fibrillation in cohort 2, although both were unrelated to active treatment.

Intravenous iscalimab treatment led to an improvement in clinical activity, as indicated by a mean reduction in European League Against Rheumatism Sjögren's syndrome disease activity index (ESSDAI) score of 5.21 points (95 percent confidence interval, 0.96–9.46) compared with placebo (p=0.0090). ESSDAI scores were similar in subcutaneous iscalimab and placebo arms.

The present data suggest that CD40–CD154 signalling is a key pathway associated with the underlying pathology of primary Sjögren’s syndrome, the researchers said, adding that the therapeutic potential of CD40 blockade in such disease should be further studied.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Elaine Soliven, 20 May 2020
Early treatment with a triple antiviral combination of lopinavir-ritonavir, ribavirin, and interferon beta-1b significantly shortens the duration of virus shedding and reduces symptoms in patients with mild-to-moderate COVID-19 compared with lopinavir-ritonavir only, according to a recent study.
Pearl Toh, 26 Sep 2019
The Singapore Health Sciences Authority (HSA) has recalled eight brands of ranitidine products containing trace amounts of the nitrosamine impurity NDMA*, which is a potential human carcinogen.
Roshini Claire Anthony, 27 May 2020

The use of a vaginal cleansing intervention prior to Caesarean delivery reduced the incidence of surgical site infections (SSIs), according to a study presented at ACOG 2020. However, the addition of intravenous (IV) azithromycin prophylaxis had no added impact on SSI rates. 

Pank Jit Sin, 14 Apr 2020
With the movement control order (MCO) in full gear, most conferences and meetings are being postponed or cancelled. Some have taken to having conferences and meetings in a virtual setting, such as the recently ended American College of Cardiology/World Congress of Cardiology (ACC.20/WCC) conference. MIMS and the Asian Young Pharmacist Group (AYPG) took this opportunity to engage with pharmacists in the form of a Zoom meeting.